Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback